Abilify Maintena

RSS

aripiprazole

Authorised
This medicine is authorised for use in the European Union.

Overview

Abilify Maintena is an antipsychotic medicine that contains the active substance aripiprazole. It is used for the maintenance treatment of schizophrenia in adults whose disease has already been stabilised with aripiprazole taken by mouth.

Schizophrenia is a mental illness with a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (false beliefs).

This EPAR was last updated on 20/07/2023

Authorisation details

Product details
Name
Abilify Maintena
Agency product number
EMEA/H/C/002755
Active substance
aripiprazole
International non-proprietary name (INN) or common name
aripiprazole
Therapeutic area (MeSH)
Schizophrenia
Anatomical therapeutic chemical (ATC) code
N05AX12
Publication details
Marketing-authorisation holder
Otsuka Pharmaceutical Netherlands B.V.
Revision
20
Date of issue of marketing authorisation valid throughout the European Union
14/11/2013
Contact address

Herikerbergweg 292
1101 CT Amsterdam
Netherlands

Product information

20/07/2023 Abilify Maintena - EMEA/H/C/002755 - N/0046

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Psycholeptics

Therapeutic indication

Maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings
3 ratings
5 ratings
3 ratings